Comparative Pharmacology
Head-to-head clinical analysis: LANABIOTIC versus ZOSYN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANABIOTIC versus ZOSYN IN PLASTIC CONTAINER.
LANABIOTIC vs ZOSYN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LANABIOTIC is a lantibiotic that inhibits bacterial cell wall synthesis by binding to lipid II, a key precursor in peptidoglycan biosynthesis, thereby disrupting cell wall integrity and causing cell death.
Piperacillin, a ureidopenicillin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors. Tazobactam, a beta-lactamase inhibitor, irreversibly inactivates beta-lactamases, preventing hydrolysis of piperacillin.
500 mg orally every 12 hours for 7-14 days.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) intravenously every 6 hours over 30 minutes. For nosocomial pneumonia, 4.5 g every 6 hours.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function; extends to 20-40 hours in severe renal impairment (CrCl <30 mL/min).
Piperacillin: 0.7-1.2 hours (normal renal function). Tazobactam: 0.7-0.9 hours. Clinically, half-life extends to 2-6 hours in renal impairment (CrCl <20 mL/min); requires dose adjustment.
Renal excretion of unchanged drug accounts for 60-80% of elimination; biliary/fecal excretion accounts for 15-30%.
Piperacillin: ~68% renal (glomerular filtration and tubular secretion), 9-17% biliary. Tazobactam: ~80% renal (unchanged and inactive metabolite). Mean cumulative urinary recovery: piperacillin 68%, tazobactam 80%; fecal recovery: piperacillin ~11%, tazobactam <1%.
Category C
Category C
Antibiotic
Antibiotic